Clinical Trial

Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) CD19 and/or BCMA.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-27.
Trial Details
NCT Number NCT07620314
Lead Sponsor Chinese PLA General Hospital
Conditions Non-Hodgkin's Lymphoma
Enrollment 9 participants
Start Date 2026-07-16
Primary Completion 2028-12-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20